Kornimate/medical-research-clean huggingface dataset:
developing an imaging-based tool to identify areas for prostate cancer biopsy

Conditions: Prostate Cancer

Summary: the purpose of the proposed research is to test and validate a risk map decision-support system (dss) for prostate cancer magnetic resonance imaging (mri) interpretation and identification of clinically significant tumor site(s).


Eligibility criteria:
inclusion criteria: * patients with known or suspected prostate cancer who have been referred to the department of radiology at the university of chicago medical center for a diagnostic mri exam of the prostate, to be followed by an mri-guided fusion biopsy of the prostate. * written informed consent. exclusion criteria: * patients incapable of giving informed written consent; * patients who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher; * patients with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders. * prisoners; * minor children (under the age of 18 years old).
d vitamin intervention in va

Conditions: Impaired Fasting Glucose; Impaired Glucose Tolerance; Vitamin D Insufficiency

Summary: this study will supplement african american male (aam) veterans at risk for diabetes and newly diagnosed t2dm with vitamin d (low or higher dose) and evaluate whether vitamin d helps to improve early markers of diabetes. the study will be done at veteran administration medical center in chicago.

the goal of this randomized clinical trial (rct) is to determine vitamin d efficacy and safety for improving early markers of t2dm in african american male (aam) veterans at risk for t2dm (n=205, duration 12 months). the primary outcome will be change in oral glucose insulin sensitivity (ogis). the secondary outcomes will include various parameters of glucose metabolism and other biomarkers. analysis based on primary and secondary goal as well as predetermined levels of a1c, ogtt and 25ohd at the end of the study.

Eligibility criteria:
inclusion criteria: veterans at jesse brown va medical center (jbvamc) only * male * african american race * age 35-85 years * bmi 28-39.9 kg/m2 * stable weight (+/- 10%) for at least 3 months prior to study entry * fpg 95 - 125 mg/dl * a1c 5.7 - 6.4% * circulating 25ohd 5.0 - 29.9 ng/ml * subjects who take ergocalciferol are allowed in the study after a washout period 1 3 month. * subjects who take vitamin d supplements other than ergocalciferol are allowed in the study as long as total dose is no more than 600 iu/day (including mvi and calcium plus d supplements). * non-diabetic subjects who are diagnosed with t2dm during screening (a1c 6.5-7%) or after randomization are allowed to continue if they follow lifestyle intervention and do not need to take anti-diabetic medications. exclusion criteria: * subjects with t2dm * weight gain or loss of more than 10% within 3 months prior to the study entry * history of kidney stones, hyperparathyroidism, sarcoidosis or hypercalcemia * a1c \>7%. * very low 25ohd levels (\<5 ng/ml) and/or the presence of a physical consequence of very low vitamin d levels (hypocalcemia, hypophosphatemia, proximal muscle weakness) * chronic kidney disease (ckd) stage 4 and 5 * problems that in the judgment of pi may be associated with the risk to the subject or non-compliance * subjects who take vitamin d supplements and not willing to go through washout period for ergocalciferol or to take no more than 600 iu/day of total vitamin d supplements * history, clinical manifestations or medications of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, psychiatric/ psychological disorders, or social circumstances which in the opinion of the investigator would be expected to interfere with the study or increase risk to the subject * non-diabetic subjects who are diagnosed with t2dm after randomization and need to take anti-diabetic medications are brought for the final visit

Keywords: vitamin d glucose intolerance african american men
the study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects in adult subjects with elevated ldl-c

Conditions: To Reduce the LDL-C Level in Hypercholesteremia Patients

Summary: this is a randomized, placebo-controlled, single ascending-dose (sad) study of administered sc to adult subjects with elevated ldl-c. subjects who have signed an ethics committee (ec)-approved informed consent form (icf) and have met all the protocol eligibility criteria during screening may be enrolled into the study.


Eligibility criteria:
inclusion criteria: 1. male and female subjects, aged 18 to 60 years, inclusive 2. body mass index between 18 and 32 kg/m2, inclusive, with body weight \> 45 kg for females and \>50 kg for males 3. serum ldl-c ≥100 mg/dl (2.6 mmol/l) at screening and day -1 4. fasting triglycerides \< 400 mg/dl (\<4.52 mmol/l) at screening and day -1 exclusion criteria: 1. known underlying disease or medical condition that may have a potential impact on general safety assessment, lipid metabolism, or glucose metabolism, or surgical condition (including, but not limited to, bariatric surgery) that, in the opinion of the investigator, may interfere with the interpretation of the results of the clinical study 2. received any medication including, but not limited to, statins, ezetimibe, or lipid-altering nutrients within 30 days prior to screening, or pcsk9 antibody within 90 days prior to screening, or any ldl-c-lowering sirna therapy within 12 months prior to screening 3. history of multiple drug allergies or allergic reactions to oligonucleotides or n-acetylglucosamine (galnac) 4. subjects with alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \> 1.5 times the upper limit of normal (uln) at the time of screening (one repeat of the screening assay is permitted) with clinically significant alt and/or ast \> uln and ≤ 1.5 times the uln as determined by the investigator 5. any medical condition that, in the opinion of the investigator, makes the subject unsuitable for enrollment or may interfere with the subject's participation in or completion of the study. this includes, but is not limited to: history or presence of cardiovascular disease (including peripheral arterial and cerebrovascular disease); diabetes mellitus (except for diabetes mellitus of pregnancy in remission); cerebrovascular accidents; and abnormal thyroid function.
to investigate effects of amway bundle combination of products on osteoarthritis & sarcopenia

Conditions: Osteoarthritis; Sarcopenia

Summary: the goal of this interventional study is to evaluate the effects of bundle combination of amway all-plant protein booster with nutrilite lifestyle guideline and/or ems (electric muscle stimulation) device on osteoarthritis \& sarcopenia in the middle-aged and elderly (50-70 years old) people. 240 eligible participants will be randomly assigned to 4 equal size study groups (ideally 52 for each group will complete the study) in the two study centers in shanghai, three site visits will be made during the 6 months of study after screening test. all clinical data will be measured /captured on paper crf(case report form) and then recorded into ctms(clinical trial data management system) for analysis and reporting. it's essential that participants should practice with the assigned guideline and device besides taking the products per day. researchers will compare the four groups to see if there is significant improvement of amway study products with bundle combination of nutrilite lifestyle guideline and/or ems on osteoarthritis \& sarcopenia in the participants.


Eligibility criteria:
inclusion criteria: * chinese males or females, age between 50-70; * sppb scale 4 - 9, but walking 400 meters within 15 minutes; * reporting \<20 min/week in the past month performing regular physical activity and \<125 min/week of moderate physical activity; * willing to comply with all research requirements and procedures; * understand the test procedure, read, and sign an appropriate informed consent form indicating their willingness to participate. exclusion criteria: * have used any medication for oa \& sa at least one month before this study. * subject having done plastic surgery for oa \& sa. * be involved in any aspect of test administration, i.e., evaluating or overseeing activities related to product. * have participated in any clinical study involving the test sites within the previous 6 months, or is subject participating in any clinical study concurrently. * have a history of any type of metabolic syndrome, including but not limited to any type of diabetes, obesity and heart disease. * have a history of any disease or the presence of health condition on the study sites that the investigator feels would interfere with the study. * be taking antihistamines (\> 3x/week) or anti-inflammatory (\> 8x/week) on a regular basis, or has the subject taken systemic or topical steroidal medications within 4 weeks of study enrolment. * have any of the following conditions or factors that the investigator believes may affect the study objectives caused by medication by protein, glucosamine, calcium and magnesium or supplements to improve capability of the sports. * have any allergy caused by all-plant protein and sea-food. * the regular exercises more than 125 minutes per week.

Keywords: amway nutrilite lifestyle ems (electric muscle stimulation)
kinetics of plasma and serum levels of brain-derived neurotrophic factor (bdnf) in patients with ischemic stroke

Conditions: Ischemic Stroke

Summary: the aim of this study is to show for the first time that treatment with intravenous fibrinolysis using rt-pa in patients with recent ischemic stroke is accompanied by increases in circulating levels of bdnf, which may reflect an increase in bdnf synthesis in the brain. the analysis of the recovery of functional and cognitive abilities as well as mood at 3 months will allow us to study the impact of bdnf on these parameters. thus, depending on the results obtained, circulating bdnf could serve as an early marker of these.


Eligibility criteria:
inclusion criteria: * patients (or their person of trust in cases of inability) who have been informed about the research and given their consent to take part * patients aged 18 years or older * patients who have suffered a de novo recent ischemic stroke \< 12 hours * patients who had cerebral imaging (ct-scan or mri) * ischemic stroke severity, measured by the national institute of health stroke score (nihss), between 4 and 20 exclusion criteria: patients without national health insurance cover * patients with a clinical history of stroke * patients with cerebral or sub-arachnoid haemorrhage * patients with a transient ischemic attack * time of symptom onset unknown * patients with severe aphasia at the time of the ischemic stroke defined by a sub-score for item 9 (best language) of the nihss ≥ 2 * patients with dementia prior to the ischemic stroke * patients with a significant loss of autonomy prior to the ischemic stroke, defined by a rankin score ≥ 4 * patients with aphasia before the ischemic stroke * patients with a contra-indication for cerebral mri * pregnant or breast-feeding women * adults under guardianship * subjects in custody * patients who do not speak french

Keywords: bdnf
attitudes and knowledge of acne in mexican adolescents

Conditions: Acne

Summary: acne is a chronic inflammatory disease that affects almost 100% of the teenagers worldwide. the peak incidence is between 12 and 18 years old, although it can be present in adults. there are many different beliefs about what can cause or exacerbate acne, and also about treatment. in mexico, 26.4% of the population is between 15 and 29 years old, which represents that more than 25% of the population is at risk for presenting acne. in our country, the different beliefs about the causes and treatment of acne among general adolescent population have not been explored. the objective of the present study is to determine the possible causes for which young mexicans do not go to the dermatologist to receive treatment for acne. our main hypothesis is that the lack of knowledge of the disease is responsible for this behavior.

acne is a chronic inflammatory disease that affects almost 100% of the teenagers worldwide. the peak incidence is between 12 and 18 years old, although it can be present in adults. there are many different beliefs about what factors can cause or exacerbate acne, as well concerning treatments. in mexico, 26.4% of the population is between 15 and 29 years old, which represents that more than 25% of the population is at risk for presenting acne. in our country, there are diverse beliefs about the causes and treatment of acne among general adolescent population which have not been explored before. the objective of the present study is to determine possible causes that are involved in the low use of health system with the intention to receive treatment for acne. the investigators' main hypothesis is that the lack of knowledge of the disease is responsible for this behavior. the investigators are going to explore health, educational, family and economic issues in the search of association by multivariate analysis.

Eligibility criteria:
inclusion criteria: * mexican subjects * age between 12 and 25 years * both genders * sign informed consent exclusion criteria: * none

Keywords: acne treatment cost behavior
pharmacological approach to improve the outcome of social cognition training

Conditions: Schizophrenia

Summary: this study will evaluate whether oxytocin will facilitate the learning of social cognitive skills in schizophrenia patients who receive 12 sessions of social cognitive skills training (scst). the primary hypothesis is that schizophrenia subjects who are treated with oxytocin will demonstrate greater improvements in a summary measure of social cognition than subjects treated with placebo over the course of scst.

individuals with schizophrenia often have serious deficits in their abilities to perceive and interpret socially relevant information. these deficits in social cognition can lead to misunderstanding the intentions of others and failing to interpret social signals that are important for successful social interactions. the relationship between social cognition and functioning has led our group to develop a research agenda that includes understanding the neural underpinnings of social cognitive deficits, measuring these impairments using brain-based biomarkers and clinical assessments, and enhancing our social cognitive skills training program to improve social cognition and promote recovery. oxytocin, which is a hormone and neurotransmitter, is believed to impact social cognition through increased orienting toward and attending to socially salient visual features. there is also evidence that oxytocinergic signaling is impaired in schizophrenia. with this research, we hope to learn whether administration of oxytocin will improve different aspects of social cognition by examining the effects of oxytocin versus placebo administered intranasally before each of 12 sessions of a social cognitive skills training program on measures of independent living, work and social functioning.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia according to the diagnostic and statistical manual of mental disorders 4th edition * stable on an antipsychotic medication * no change in antipsychotic dose of \>10% during the past 3 months exclusion criteria: * unable to provide informed consent * history of epilepsy * active medical conditions that would make the study unsafe * history of serious head injury * history of hyponatremia

Keywords: schizophrenia social cognition oxytocin
doxycycline outcomes in lupus erythematosus

Conditions: Cardiovascular Disease

Summary: cardiovascular disease, specifically from atherosclerosis, is the major cause of mortality in sle in developed countries. in a recent study the investigators have shown that high sensitivity c reactive protein (hs-crp) is higher in sle patients with (versus without) coronary calcium, a measure of subclinical atherosclerosis. in an ongoing two year intervention trial of atorvastatin, the investigators will determine if statins retard coronary calcium and reduce hs-crp. however, 10% of the patients in the trial were intolerant of statins. the investigators want to now investigate whether there are additional, and potentially safer ways, to reduce hs-crp in sle. in this study, the investigators will determine if doxycycline reduces hs-crp and other vascular inflammatory markers including interleukin 6 (il-6), soluble vascular cell adhesion molecule (svcam-1), soluble inter cell adhesion molecule (s-icam-1) and matrix metalloproteinase 9 (mmp-9) in sle.


Eligibility criteria:
inclusion criteria: 1. patients with a clinical diagnosis of sle, with a hs-crp above \> 3mg/l, (high risk level) for the last 3 months, are eligible. 2. patients must be 18 years of age or older and able to give informed consent. 3. contraception other than ocps is necessary if a woman is at risk for pregnancy. exclusion criteria: 1. sle patients who are allergic to doxycycline or other tetracyclines. 2. patients who are pregnant or are planning to become pregnant. 3. patients who are on oral contraceptives (any method of contraception other than ocps can be used. 4. tetracycline use within the previous 2 weeks of enrollment. 5. patients who are currently on statins will be excluded, because statins might reduce hs- crp. 6. patients who are on warfarin. 7. patients whose most recent ekg shows significant cardiac dysrhythmias or heart block.

Keywords: inflammatory markers of cardiovascular disease
obstructive sleep apnoea in children and adolescents with ehlers-danlos syndrome

Conditions: Ehler's Danlos Syndrome; Obstructive Sleep Apnea

Summary: ehlers-danlos syndrome (eds) is a clinically and genetically heterogeneous group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. eds features such as genetically related cartilage defects, craniofacial abnormalities and increased pharyngeal collapsibility have been proposed to cause obstructive sleep apnoea (osa). there is evidence from studies based on questionnaires that eds patients might be more frequently affected by osa and sleep disturbances than the general population. however, the actual prevalence of osa in children and adolescents with eds is unknown. the primary objective of this study is to assess the prevalence of osa in children and adolescents with eds (25) compared to a matched control group (25). the secondary objective of this pioneer study is to assess the quality of life in children and adolescents in eds in comparison to healthy children and adolescents.

ehlers-danlos syndrome (eds) is a clinically and genetically heterogeneous group of inherited connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. eds features such as genetically related cartilage defects, craniofacial abnormalities and increased pharyngeal collapsibility have been proposed to cause obstructive sleep apnoea (osa). there is evidence from studies based on questionnaires that eds patients might be more frequently affected by osa and sleep disturbances than the general population. however, the actual prevalence of osa in children and adolescents with eds is unknown. the primary objective of this study is to assess the prevalence of osa in children and adolescents with eds compared to a matched control group. the secondary objective of this pioneer study is to assess the quality of life in children and adolescents in eds in comparison to healthy children and adolescents.

Eligibility criteria:
inclusion criteria: * informed consent * diagnosis of ehlers-danlos syndrome (not for control group) exclusion criteria: * moribund or severe disease prohibiting protocol adherence * continuous positive airway pressure treatment for osa during sleep study * physical or intellectual impairment precluding informed consent or protocol adherence * pregnant patients

Keywords: ehlers-danlos syndrome obstructive sleep apnea prevalence children pediatric adolescents
increasing statin prescribing in hiv behavioral economics research

Conditions: HIV; Cardiovascular Diseases

Summary: cardiovascular disease is a major cause of morbidity and mortality among people living with hiv. recent studies have demonstrated that patients with hiv experience a 50-100% increased risk of myocardial infarction and stroke compared to hiv-uninfected persons. they also face higher risks of stroke, sudden death, and heart failure. however, evidence-based statin therapy-which is safe in this population and highly effective at reducing cardiovascular risk-is under-prescribed. the investigators propose a multi-level intervention to increase evidence-based statin prescribing by addressing barriers at these levels. the implementation intervention includes two strategies: (1) tailored education at the leadership, provider, and patient levels, and (2) behavioral economics-informed feedback for providers.


Eligibility criteria:
inclusion criteria: * age ≥ 40 years * have been diagnosed with hiv * ldl ≥ 190, diabetes and ldl ≥ 70 * or 10-year ascvd risk ≥ 7.5% * or history of heart attack, stroke, or peripheral vascular disease * care for patients with hiv at least 1/2 day each week (physicians) * work at participating clinics (physicians) exclusion criteria: * unable to provide written, informed consent * not at participating clinic
diagnostic importance of the circulating human leucine-rich α-2-glycoprotein in acute appendicitis in pediatric patients

Conditions: Appendicitis Acute

Summary: acute appendicitis is a common and potentially serious medical condition which can be difficult to diagnose, especially in pediatric patients. to help recognize patients with acute appendicitis, number of laboratory and radiological test are used. previous research has shown that circulating human leucine-rich α-2-glycoprotein (lgr1) in the blood can be elevated in pediatric patients with acute appendicitis. the aim of this research is to analyse whether lgr1 levels in saliva can be used as a less invasive diagnostic method in pediatric patients with suspected acute appendicitis.


Eligibility criteria:
inclusion criteria: * children with age from 5 do 17 with acute abdominal pain * children with clinical signs of appendicitis exclusion criteria: * previous diagnosis of chronic and/or malignant disease * children which had previous abdominal surgery * pregnancy